Daiichi Sankyo Co Ltd (DSKYF)
35.11
-0.51
(-1.43%)
USD |
OTCM |
May 17, 15:46
Daiichi Sankyo Enterprise Value: 60.89B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 60.89B |
| May 15, 2024 | 59.75B |
| May 14, 2024 | 60.33B |
| May 13, 2024 | 60.98B |
| May 10, 2024 | 58.22B |
| May 09, 2024 | 57.40B |
| May 08, 2024 | 57.61B |
| May 07, 2024 | 59.76B |
| May 06, 2024 | 62.04B |
| May 03, 2024 | 62.40B |
| May 02, 2024 | 60.04B |
| May 01, 2024 | 58.45B |
| April 30, 2024 | 56.42B |
| April 29, 2024 | 55.45B |
| April 26, 2024 | 53.66B |
| April 25, 2024 | 50.69B |
| April 24, 2024 | 52.01B |
| April 23, 2024 | 51.66B |
| April 22, 2024 | 50.97B |
| April 19, 2024 | 50.69B |
| April 18, 2024 | 49.63B |
| April 17, 2024 | 46.70B |
| April 16, 2024 | 47.81B |
| April 15, 2024 | 48.08B |
| April 12, 2024 | 49.00B |
| Date | Value |
|---|---|
| April 11, 2024 | 47.45B |
| April 10, 2024 | 48.25B |
| April 09, 2024 | 50.78B |
| April 08, 2024 | 53.22B |
| April 05, 2024 | 51.81B |
| April 04, 2024 | 51.55B |
| April 03, 2024 | 50.71B |
| April 02, 2024 | 52.05B |
| April 01, 2024 | 52.87B |
| March 31, 2024 | 54.73B |
| March 28, 2024 | 54.44B |
| March 27, 2024 | 54.44B |
| March 26, 2024 | 53.65B |
| March 25, 2024 | 54.71B |
| March 22, 2024 | 53.23B |
| March 21, 2024 | 53.08B |
| March 20, 2024 | 55.21B |
| March 19, 2024 | 53.14B |
| March 18, 2024 | 54.44B |
| March 15, 2024 | 51.72B |
| March 14, 2024 | 54.21B |
| March 13, 2024 | 53.39B |
| March 12, 2024 | 52.83B |
| March 11, 2024 | 54.25B |
| March 08, 2024 | 56.91B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
25.48B
Minimum
Aug 09 2021
67.57B
Maximum
Jun 13 2023
45.88B
Average
47.04B
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 70.65B |
| Nxera Pharma Co Ltd | 1.009B |
| PeptiDream Inc | 1.744B |
| Healios KK | 63.48M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 250.42M |
| Revenue (Quarterly) | 2.887B |
| Total Expenses (Quarterly) | 2.772B |
| EPS Diluted (Quarterly) | 0.1305 |
| Gross Profit Margin (Quarterly) | 75.59% |
| Profit Margin (Quarterly) | 8.68% |
| Earnings Yield | 2.07% |
| Operating Earnings Yield | 2.17% |
| Normalized Earnings Yield | 2.069 |